Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.

Efimenko E, Davé UP, Lebedeva IV, Shen Y, Sanchez-Quintero MJ, Diolaiti D, Kung A, Lannutti BJ, Chen J, Realubit R, Niatsetskaya Z, Ten V, Karan C, Chen X, Califano A, Diacovo TG.

Mol Cancer Ther. 2017 Oct;16(10):2069-2082. doi: 10.1158/1535-7163.MCT-17-0141. Epub 2017 Jul 17.

2.

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, Chiorazzi N, Izumi R, Ulrich R, Lannutti BJ, Wiestner A, Herman SEM.

Clin Cancer Res. 2017 Oct 1;23(19):5814-5823. doi: 10.1158/1078-0432.CCR-17-0650. Epub 2017 Jun 23.

PMID:
28645939
3.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA.

Clin Cancer Res. 2017 Jun 1;23(11):2831-2841. doi: 10.1158/1078-0432.CCR-16-0463. Epub 2016 Nov 30.

4.

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR.

N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.

5.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE.

Oncotarget. 2014 Feb 28;5(4):908-15.

6.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR.

Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.

7.

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.

Goodwin CB, Li XJ, Mali RS, Chan G, Kang M, Liu Z, Vanhaesebroeck B, Neel BG, Loh ML, Lannutti BJ, Kapur R, Chan RJ.

Blood. 2014 May 1;123(18):2838-42. doi: 10.1182/blood-2013-10-535104. Epub 2014 Feb 19.

8.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.

PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013.

9.

Putative roles for PI3K α and δ isoforms in refractory mantle cell lymphoma.

Jessen KA, Lannutti BJ.

Acta Haematol. 2014;131(4):218-9. doi: 10.1159/000355636. Epub 2013 Nov 30. No abstract available.

PMID:
24296619
10.

Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.

Shugg RP, Thomson A, Tanabe N, Kashishian A, Steiner BH, Puri KD, Pereverzev A, Lannutti BJ, Jirik FR, Dixon SJ, Sims SM.

J Biol Chem. 2013 Dec 6;288(49):35346-57. doi: 10.1074/jbc.M113.507525. Epub 2013 Oct 16.

11.
12.

Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S.

Cell Cycle. 2013 Jun 15;12(12):1892-900. doi: 10.4161/cc.24928. Epub 2013 May 15.

13.

Specific inhibition of PI3K p110δ inhibits CSF-1-induced macrophage spreading and invasive capacity.

Mouchemore KA, Sampaio NG, Murrey MW, Stanley ER, Lannutti BJ, Pixley FJ.

FEBS J. 2013 Nov;280(21):5228-36. doi: 10.1111/febs.12316. Epub 2013 Jun 5.

14.

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.

Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.

Blood. 2012 Oct 25;120(17):3501-9. doi: 10.1182/blood-2012-02-414060. Epub 2012 Sep 5.

15.

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.

Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC.

Cancer Cell. 2012 May 15;21(5):694-708. doi: 10.1016/j.ccr.2012.03.040.

16.

Targeting nonclassical oncogenes for therapy in T-ALL.

Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG.

Cancer Cell. 2012 Apr 17;21(4):459-72. doi: 10.1016/j.ccr.2012.02.029.

17.

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ.

Blood. 2012 Feb 23;119(8):1897-900. doi: 10.1182/blood-2011-10-386763. Epub 2011 Dec 30.

18.

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA.

Blood. 2011 Sep 29;118(13):3603-12. doi: 10.1182/blood-2011-05-352492. Epub 2011 Jul 29.

19.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ.

Blood. 2011 Apr 21;117(16):4323-7. doi: 10.1182/blood-2010-11-315705. Epub 2011 Mar 4.

20.

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA.

Blood. 2011 Jan 13;117(2):591-4. doi: 10.1182/blood-2010-03-275305. Epub 2010 Oct 19.

21.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ.

Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.

22.

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cristea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.

Blood. 2010 Sep 2;116(9):1460-8. doi: 10.1182/blood-2009-06-222943. Epub 2010 May 26.

23.

Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.

Lannutti BJ, Epp A, Roy J, Chen J, Josephson NC.

Blood. 2009 Feb 19;113(8):1778-85. doi: 10.1182/blood-2007-11-124859. Epub 2008 Sep 16.

24.

Expression of the GPI-anchored receptor Prv-1 enhances thrombopoietin and IL-3-induced proliferation in hematopoietic cell lines.

Dillon M, Minear J, Johnson J, Lannutti BJ.

Leuk Res. 2008 May;32(5):811-9. Epub 2007 Nov 5.

PMID:
17980909
25.

Increased megakaryocytopoiesis in Lyn-deficient mice.

Lannutti BJ, Minear J, Blake N, Drachman JG.

Oncogene. 2006 Jun 1;25(23):3316-24. Epub 2006 Jan 16.

PMID:
16418722
26.

A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells.

Gandhi MJ, Drachman JG, Reems JA, Thorning D, Lannutti BJ.

Blood Cells Mol Dis. 2005 Jul-Aug;35(1):70-3.

PMID:
15923131
27.

Induction of polyploidization in leukemic cell lines and primary bone marrow by Src kinase inhibitor SU6656.

Lannutti BJ, Blake N, Gandhi MJ, Reems JA, Drachman JG.

Blood. 2005 May 15;105(10):3875-8. Epub 2005 Jan 27.

28.
29.

Identification and activation of Src family kinases in primary megakaryocytes.

Lannutti BJ, Shim MH, Blake N, Reems JA, Drachman JG.

Exp Hematol. 2003 Dec;31(12):1268-74.

PMID:
14662334
30.

Gprk2 controls cAMP levels in Drosophila development.

Lannutti BJ, Schneider LE.

Dev Biol. 2001 May 1;233(1):174-85.

31.

In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model.

Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS.

J Invest Dermatol. 1999 May;112(5):775-81.

32.

Integrin alpha 5 beta 1 expression is required for inhibition of keratinocyte migration by ganglioside GT1b.

Sung CC, O'Toole EA, Lannutti BJ, Hunt J, O'Gorman M, Woodley DT, Paller AS.

Exp Cell Res. 1998 Mar 15;239(2):311-9.

PMID:
9521848
33.

Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo.

Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS.

Cancer Res. 1997 Dec 1;57(23):5277-80.

Supplemental Content

Loading ...
Support Center